This course summarizes the best of Lung track with the following abstracts:
- RTOG0617 to externally validate blood cell ERCC1/2 genotypic signature as a radiosensitivity biomarker for both tumor and normal tissue for individualized dose prescription
- Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial
- Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)
- Randomized phase II trial of metformin in combination with chemoradiotherapy (CRT) in locally advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464).
- Individualized Adaptive Radiotherapy versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601
- A Phase III Randomized Trial of Palliative Radiation for Advanced Central Lung Tumours with Intentional Avoidance of the Esophagus (PROACTIVE)
- Assessment of Coronary Artery Calcification Burden as a Risk Factor for Cardiac Toxicity in Patients Treated on Radiation Dose-escalation Trials for Stage III Non-small-cell Lung Cancer
- Statin Use and Major Adverse Cardiac Events among High Cardiac Risk Patients with Lung Cancer Receiving Radiotherapy
- Patterns of Disease Progression After Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
- Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia
The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, learners should be able to do the following:
- Recognize the Role of Prophylactic Cranial Irradiation in Patients with Extensive-Stage Small Cell Lung Cancer.
- Apply Stereotactic Body Radiation Therapy (SBRT)/Stereotactic Ablative Radiotherapy (SABR) with Accepted Fractionation Regimen in Patients with Stage IV Non-Small Cell Lung Cancer.
- Design Radiation Treatment Plans with Effective Avoidance of Organs at Risk, e.g. Heart, Esophagus, Lungs, etc.
Andreas Rimner, MD is employed by Memorial Sloan Kettering Cancer Center and receives compensation/remuneration/funding from Varian Medical Systems, Pfizer, Cybrexa, Boehringer Ingelheim, AstraZeneca and Merck.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.